Patents Represented by Attorney, Agent or Law Firm Iver P. Cooper
-
Patent number: 8343739Abstract: A genetically engineered micro-organism having an operative metabolic pathway producing cinnamoyl-CoA and producing pinosylvin therefrom by the action of a stilbene synthase is used for pinosylvin production. Said cinnamic acid may be formed from L-phenylalanine by a L-phenylalanine ammonia lyase (PAL) which is one accepting phenylalanine as a substrate and producing cinammic acid therefrom, preferably such that if the PAL also accepts tyrosine as a substrate and forms coumaric acid therefrom, the ratio Km(phenylalanine)/Km(tyrosine) for said PAL is less than 1:1 and if said micro-organism produces a cinammate-4-hydroxylase enzyme (C4H), the ratio Kcat(PAL)/Kcat(C4H) is at least 2:1.Type: GrantFiled: July 19, 2007Date of Patent: January 1, 2013Assignee: Fluxome Sciences A/SInventors: Michael Katz, Jochen Förster, Helga David, Hans Peter Schmidt, Malin Sendelius, Sara Peterson Bjørn, Thomas Thomasen Durhuus
-
Patent number: 8263567Abstract: The present invention relates to pharmaceutical formulations comprising an anthracycline and the uses thereof for treatment of clinical conditions of body surfaces such as skin and mucosal membranes, wherein abnormal cell differentiation and/or hyperproliferation is a primary factor of the pathogenesis. In particular the invention relates to treatment of psoriasis, and preferably to treatment of psoriasis with valrubicin topically applied.Type: GrantFiled: January 28, 2008Date of Patent: September 11, 2012Assignee: Valderm APSInventors: Bjarne Bymose, Thomas Broe Christensen
-
Patent number: 8138148Abstract: The present invention relates to peptide fragments derived from the proteins belonging to the TGFbeta superfamily, pharmaceutical compositions comprising these peptide fragments and uses thereof for treatment of a disease or condition wherein the effects of stimulating neuronal cell differentiation, neuronal cell survival, stimulating neural plasticity associated with learning and memory and/or inhibiting inflammatory response are beneficial for treatment.Type: GrantFiled: August 15, 2006Date of Patent: March 20, 2012Assignee: Copenhagen UniversityInventors: Elisabeth Bock, Vladimir Berezin
-
Patent number: 8071549Abstract: The present invention relates to a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, capable of interacting with an Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1, and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to a pharmaceutical composition comprising said compound, a process of producing a pharmaceutical composition and the use of said compound.Type: GrantFiled: May 4, 2009Date of Patent: December 6, 2011Inventors: Vladislav V Kiselyov, Galina Skladchikova, Vladimir Berezin, Elisabeth Bock
-
Patent number: 8043843Abstract: Mutants of lactic acid bacteria including Lactococcus lactis which are defective in pyruvate formate-lyase production and/or in their lactate dehydrogenase (Ldh) production and methods of isolating such mutants or variants are provided. The mutants are useful in the production of food products or in manufacturing of compounds such as diacetyl, acetoin and acetaldehyde and as components of food starter cultures.Type: GrantFiled: December 11, 2008Date of Patent: October 25, 2011Inventor: Dan Nilsson
-
Patent number: 8008259Abstract: The present invention relates to peptide sequences capable of stimulating neuronal cell differentiation, neural cell survival and neuronal plasticity associated with memory and learning. The peptide sequences of the invention are derived from the proteins belonging to neurotrophic factors, such as NGF, NT3, NT4/5 and BDNF. The invention also relates to pharmaceutical compositions comprising said peptide fragments and uses thereof for treatment of a disease or condition wherein the effects of stimulating neuronal cell differentiation, neuronal cell survival, stimulating neural plasticity associated with learning and memory are beneficial for treatment.Type: GrantFiled: November 7, 2006Date of Patent: August 30, 2011Assignee: Copenhagen University, Techtrans UnitInventors: Elisabeth Bock, Vladimir Berezin
-
Patent number: 8003688Abstract: The present invention relates to methods of treating conditions and/or symptoms related to common cold of the upper and/or lower respiratory tract and/or eyes. In particular the invention relates to the methods of treating conditions and/or symptoms related to common cold comprising administration of a flavonoid or administration of a flavonoid in combination with a metal. The invention furthermore describes compositions comprising a metal and a flavonoid useful for the treatment of conditions and/or symptoms relates to common cold.Type: GrantFiled: July 5, 2005Date of Patent: August 23, 2011Assignee: ImmuPharm ApsInventor: Kurt Frimman Berg
-
Patent number: 7951906Abstract: The present invention relates to a method for modulating the interaction between at least two proteins, wherein at least one of the two proteins is a functional cell-surface receptor and the other protein is the receptor ligand. The invention features a binding site of said functional cell-surface receptor on the receptor ligand and discloses a series of amino acid sequences, which are part of the structure of said binding site and/or involved in the interaction between the receptor and the ligand. Moreover, the present invention features methods for molecular design and screening of a candidate compound capable of modulating the interaction between the functional cell-surface receptor and receptor ligand through the described binding site, and provides a screening assay for identification of such a compound.Type: GrantFiled: February 12, 2009Date of Patent: May 31, 2011Assignee: Enkam Pharmaceuticals A/SInventors: Elisabeth Bock, Vladimir Berezin, Morten Albrechtsen
-
Patent number: 7928206Abstract: This invention relates to novel plant thymidine kinases and their use in gene therapy. More specifically the invention provides novel thymidine kinases derived from tomato. In further aspects the invention provides novel polynucleotides encoding the tomato thymidine kinase of mutant thereof, vector constructs comprising the polynucleotide, host cells carrying the polynucleotide or vector, methods of sensitising cells to prodrugs, methods of inhibiting pathogenic agents in warm-blooded animals, methods for biocontrol of plants, methods of synthesizing monophosphates and pharmaceutical compositions comprising the plant thymidine kinases of the invention. In a preferred embodiment the invention provides a unique combination of a plant thymidine kinase and the nucleoside analog nucleoside analog AZT (3?-azido-3?-deoxythymidine) to treat abnormal cell growth.Type: GrantFiled: May 21, 2003Date of Patent: April 19, 2011Inventors: Wolfgang Knecht, Birgitte Munch-Petersen, Jure Piskur
-
Patent number: 7915201Abstract: The invention relates to a method for synthesising a bifunctional complex comprising an encoded molecule and an identifier polynucleotide identifying the chemical entities having participated in the synthesis of the encoded molecule, said method comprising the steps of i) providing a) at least one template comprising one or more codons capable of hybridising to an anti-codon, wherein said template is optionally associated with one or more chemical entities, and b) a plurality of building blocks each comprising an anti-codon associated with one or more chemical entities, and ii) hybridising the anti-codon of one or more of the provided building blocks to the template, iii) covalently linking said anti-codons and/or linking the at least one template with the anti-codon of at least one building block, thereby generating an identifier polynucleotide capable of identifying chemical entities having participated in the synthesis of the encoded molecule, iv) separating the template from one or more of the anti-codonsType: GrantFiled: March 22, 2004Date of Patent: March 29, 2011Assignee: Nuevolution A/SInventors: Thomas Franch, Soeren Nyboe Jacobsen, Torben Ravn Rasmussen, Soeren Neve, Henrik Pedersen, Alex Haahr Gouliaev
-
Patent number: 7892583Abstract: The present invention discloses microbial organisms capable of fermenting malic acid to lactic acid having impaired capability of degrading citric acid. These microbial organisms are for example useful in methods of preferentially degrading malic acid over citric acid in a liquid composition or in methods of inducing malolactic fermentation during wine production. The invention also discloses a concentrate of these microbial organisms and methods of preparing such a concentrate. The present invention furthermore relates to an activation solution useful for incubation of microbial organisms prior to inoculation into a liquid composition, such as wine.Type: GrantFiled: June 25, 2004Date of Patent: February 22, 2011Assignee: CHR. Hansen A/SInventor: Jan Clair Nielsen
-
Patent number: 7883884Abstract: The present invention concerns an anaerobic digestion of animal manures, energy crops and similar organic substrates. The process is capable of refining nutrients comprised in the digested biomass to fertilizers of commercial quality. The invention also provides a method for oprocessing animal carcasses or fractions thereof including meat and bone meal etc., with the objective of providing an alternative means for processing the organic waste material of animal origin while at the same time facilitating the production of fertilizers. The risk of spreading BSE prions or any other prions to animals or humans is thus substantially reduced if not eliminated. The biogas and slurry separation system according to the present invention is preferably integrated with the operations of animal husbandries into a total concept in which the internal and external performances of animal husbandries are optimised.Type: GrantFiled: August 22, 2001Date of Patent: February 8, 2011Assignee: GFE Patent A/SInventors: Torben Bonde, Lars Jorgen Pedersen
-
Patent number: 7869011Abstract: The present invention relates to an apparatus for analysing beads and particles, such as polymer beads used e.g. for solid phase synthesis. The apparatus comprises a) a vacuum container comprising at least one planar capture body capable of rotating around a central axis, wherein said capture body comprises a plurality of through-going inlets, and wherein the diameter of each inlet is smaller than the average diameter of the beads to be measured and/or analysed and/or sorted, b) a pressure controlling device capable of controlling the pressure in the vacuum container, c) a device for rotating the vacuum container around the axis of the capture body, and d) a device for measuring at least one property of at least one bead, the apparatus further comprising a capture body support, supporting the capture body, and a vacuum container housing.Type: GrantFiled: December 22, 2004Date of Patent: January 11, 2011Assignee: Novo Norkisk A/SInventors: Soeren Flygenring Christensen, Ib Johannsen
-
Patent number: 7847058Abstract: The present invention relates to a method of modulating differentiation, adhesion and/or survival of the neural cell adhesion molecule (NCAM) presenting cells by providing compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM. The invention provides candidate compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM by using methods for screening and testing described in the application. The invention further relates to pharmaceutical compositions comprising compounds capable of modulating the interaction between the Ig1, Ig2 and/or Ig3 modules of NCAM and to use of the pharmaceutical compositions and compounds for the modulation of differentiation, adhesion and/or survival of NCAM presenting cells.Type: GrantFiled: September 29, 2004Date of Patent: December 7, 2010Inventors: Elisabeth Bock, Vladimir Berezin, Vladyslav Soroka, Christina Kasper, Jette Sandholm Jensen Kastrup
-
Patent number: 7842294Abstract: The present invention relates to proteins belonging to the Bcl-2 family and peptides fragments thereof for use in pharmaceutical compositions. The disclosed proteins and peptide fragments are in particularly useful in vaccine compositions for treatment of cancer. The invention furthermore relates to methods of treatment using said compositions. It is also an aspect of the invention to provide T-cells and T-cell receptors specifically recognising the disclosed proteins and peptide fragments.Type: GrantFiled: November 18, 2004Date of Patent: November 30, 2010Assignee: Survac APSInventors: Mads Hald Andersen, Per Thor Straten
-
Patent number: 7781207Abstract: The present invention relates to a method and a system for producing a mammalian pre-embryo and a stem cell having a better quality than prior art methods. The system comprises means for obtaining a mammalian oocyte, and means for obtaining a mammalian spermatozoa, and an apparatus having at least two separate air-tight chambers, for which the oxygen tension of one chamber may be changed independent of the oxygen tension of the other chamber, said at least two separate air-tight chambers constitute a main chamber and at least one residence chamber.Type: GrantFiled: June 10, 2009Date of Patent: August 24, 2010Assignee: Region Hovedstaden v/Herlev HospitalInventor: Svend Lindenberg
-
Patent number: 7741297Abstract: Covalently lipidated oligonucleotides comprising the CpG dinucleotide unit, or an analogue thereof, may be used as immunostimulatory agents to protect against a disease caused by a cancer cell or a pathogen, either alone or in conjunction with immunogens and/or non-immunological agents. Lipidated oligonucleotides with special backbones, lipidated oligonucleotides with fewer than eight nucleotides, and lipidated oligonucleotides comprising a plurality of CpG dinucleotide-containing segments connected by a long internucleoside linkage are of particular interest. These compounds are also novel per se.Type: GrantFiled: February 4, 2003Date of Patent: June 22, 2010Assignee: Oncothyreon Inc.Inventors: Zi-Hua Jiang, Rao Koganty, Damayanthi Yalamati, Myung-Gi Baek
-
Patent number: 7727713Abstract: The present invention relates to a method for synthesizing templated molecules. In one aspect of the invention, the templated molecules are linked to the template which templated the synthesis thereof. The intion allows the generation of libraries which can be screened for e.g. therapeutic activity.Type: GrantFiled: June 20, 2002Date of Patent: June 1, 2010Assignee: Nuevolution A/SInventors: Henrik Pedersen, Alex Haahr Gouilaev, Thomas Franch, Christian Klarner Sams, Eva Kampmann Olsen, Frank Abilgaard Sløk, Gitte Nystrup Husemoen, Jakob Felding, Lene Hyldtoft, Mads Nørregaard-Madsen, Michael Anders Godskesen, Sanne Schrøder Glad, Thomas Thisted, Per-Ola Freskgård, Anette Holtmann
-
Patent number: 7704925Abstract: The present invention in one aspect relates to a method for synthesizing a bifunctional complex comprising a molecule and an identifier polynucleotide identifying at least some of the chemical entities which have participated in the synthesis of the molecule in accordance with the methods of the present invention. The invention also relates to a library of different bifunctional complexes. The library of the invention can be used e.g. for identifying drug leads. Furthermore, the present invention is based on the principle that chemical entities initially provided on a building block oligonucleotide (i.e. a building block having an oligonucleotide part which is linked to a chemical entity) can be brought into reactive proximity without the use of a template comprising a set of covalently linked codons.Type: GrantFiled: March 22, 2005Date of Patent: April 27, 2010Assignee: Nuevolution A/SInventors: Alex Haahr Gouliaev, Henrik Pedersen
-
Patent number: 7671086Abstract: The present invention relates to use of certain antiviral fragrances for reduction of viruses, in particular vira causing common cold. In one embodiment, the invention relates to pharmaceutical compositions comprising an antiviral fragrance, preferably menthol. Said compositions preferably also comprise one or more flavonoids. The invention also relates to treatment of common cold using said compositions.Type: GrantFiled: May 15, 2009Date of Patent: March 2, 2010Assignee: Immupharm A/SInventor: Kurt Frimann Berg